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A B S T R A C T   
Introduction: The National Comprehensive Cancer Network guidelines recommend re-challenge with the first-line 
treatment for relapsed small cell lung cancer (SCLC) with chemotherapy-free interval (CTFI)≥180 days. A phase 
II study (NCT02454972) showed remarkable antitumor activity in SCLC patients treated with lurbinectedin 
3.2 mg/m2 1 -h intravenous infusion every 3 weeks as second-line therapy. We report results for the pre-planned 
subset of patients with CTFI ≥ 180 days. 
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Material and Methods: Twenty patients aged ≥18 years with pathologically proven SCLC diagnosis, pretreated 
with only one prior platinum-containing line, no CNS metastases, and with CTFI ≥ 180 days were evaluated. The 
primary efficacy endpoint was the overall response rate (ORR) assessed by the Investigators according to RECIST 
v1.1. 
Results: ORR was 60.0 % (95 %CI, 36.1− 86.9), with a median duration of response of 5.5 months (95 %CI, 
2.9− 11.2) and disease control rate of 95.0 % (95 %CI, 75.1− 99.9). Median progression-free survival was 4.6 
months (95 %CI, 2.6− 7.3). With a censoring of 55.0 %, the median overall survival was 16.2 months (95 %CI, 
9.6-upper level not reached). Of note, 60.9 % and 27.1 % of patients were alive at 1 and 2 years, respectively. The 
most common grade 3/4 adverse events and laboratory abnormalities were hematological disorders (neu-
tropenia, 55.0 %; anemia; 10.0 % thrombocytopenia, 10.0 %), fatigue (10.0 %) and increased liver function tests 
(GGT, 10 %; ALT and AP, 5.0 % each). No febrile neutropenia was reported. 
Conclusion: Lurbinectedin is an effective treatment for platinum-sensitive relapsed SCLC, especially in patients 
with CTFI ≥ 180 days, with acceptable safety and tolerability. These encouraging results suggest that lurbi-
nectedin can be another valuable therapeutic option rather than platinum re-challenge.   
1. Introduction 
Standard first-line chemotherapy for patients with small cell lung 
cancer (SCLC) consists of a platinum salt (carboplatin or cisplatin) in 
combination with etoposide [1,2]. Recently, atezolizumab [3] or dur-
valumab [4] plus carboplatin/etoposide showed improved survival 
compared to chemotherapy alone, and both have been approved by the 
US FDA as first-line therapy. However, therapeutic options are limited 
once patients with SCLC have relapsed disease. The National Compre-
hensive Cancer Network (NCCN) and the European Society of Medical 
Oncology (ESMO) guidelines recommend re-challenge with the first-line 
regimen in relapsed SCLC patients with sensitive disease, defined as 
patients with a chemotherapy-free interval (CTFI) ≥90 days in the 
ESMO guidelines and patients with a CTFI ≥ 180 days in the NCCN 
guidelines [1,2]. 
During the last decade, few studies have published data on re- 
challenge with platinum-based therapy after failure of the first-line 
treatment in SCLC patients with sensitive disease [5–12]. Most of 
these studies are small retrospective analyses, usually including patients 
with CTFI ≥ 90 days, and mostly include Japanese patients [6,7,9–11]. 
In the largest retrospective analysis conducted to date (n = 112 pa-
tients), Genestreti et al. [8] showed an overall response rate (ORR) of 45 
% and median overall survival (OS) of 7.9 months. More recently, 
Monnet et al. [12] reported data of 81 patients from the GFPC 13− 01 
randomized phase III trial evaluating platinum re-challenge versus top-
otecan: ORR was 49 % with re-challenge vs. 25 % with topotecan, me-
dian progression-free survival (PFS) was 4.7 months vs. 2.7 months, and 
median OS was 7.5 months vs. 7.4 months. 
Limited information is available on platinum re-challenge in 
relapsed SCLC patients with CTFI ≥ 180 days. A phase II randomized 
study evaluating amrubicin versus platinum re-challenge included 18 of 
30 patients (60.0 %) with relapse after CTFI ≥ 180 days: ORR with re- 
challenge was 43 % and median OS was 14.3 months [6]. Only one 
small retrospective study (n = 11 Japanese patients) included data 
exclusively obtained from patients with CTFI ≥ 180 days: ORR was 46 % 
and median OS was 15.7 months [7]. 
SCLC is a difficult-to-treat disease addicted to transcription [13], 
without actionable targets being identified. Four molecular SCLC sub-
types recently have been described, defined by differential expression of 
four key transcription regulators [14]. Lurbinectedin (ZEPZELCA™, 
PharmaMar, Madrid, Spain) is a selective inhibitor of oncogenic tran-
scription that binds preferentially to guanines located in the GC-rich 
regulatory areas of DNA gene promoters [15,16]. By preventing bind-
ing of transcription factors to their recognition sequences, the drug in-
hibits oncogenic transcription and leads to tumor cell apoptosis [17]. 
Lurbinectedin also affects the tumor microenvironment landscape by 
inhibiting activated transcription in tumor-associated macrophages 
[18]. 
Recently, in June 2020, the US FDA granted accelerated approval to 
lurbinectedin for adult patients with metastatic SCLC with disease 
progression on or after platinum-based chemotherapy based on results 
from a phase II study (study B-005; NCT02454972). This pivotal study 
showed remarkable antitumor activity in 60 SCLC patients with 
CTFI ≥ 90 days treated with lurbinectedin as second-line: ORR of 45.0 
%, median duration of response of 6.2 months and median OS of 11.9 
months [19]. The NCCN guidelines updated on 7 July 2020 have added 
lurbinectedin as a preferred treatment for patients with relapsed SCLC 
and CTFI ≤ 180 days, and as a recommended regimen other than 
re-challenge with the initial therapy for patients with CTFI > 180 days 
[2]. We show here results for the subset of patients in this phase II study 
who are candidates for platinum re-challenge according to the NCCN 
guidelines (patients with CTFI ≥ 180 days). 
2. Methods 
2.1. Patients 
In this phase II study, 105 SCLC patients were treated between 
October 2015 and January 2019 in 26 hospitals from 6 European 
countries and the USA [19]. Patients were ≥ 18 years old with patho-
logically proven SCLC diagnosis; pretreated with one prior 
platinum-containing line; with measurable disease as per the Response 
Criteria in Solid Tumors (RECIST) v.1.1 [20] and Eastern Cooperative 
Oncology Group performance status (ECOG PS) ≤2; and adequate bone 
marrow, renal, and liver function. Patients were excluded if they had: 
previously received lurbinectedin or trabectedin; prior or concurrent 
malignant disease unless in complete remission for more than 5 years; 
central nervous system involvement; concomitant unstable or serious 
medical condition (history or presence of unstable angina, myocardial 
infarction, congestive heart failure, valvular heart disease, arrhythmia, 
severe dyspnea, or active infection), or impending need for 
radiotherapy. 
The study was conducted in accordance with the Declaration of 
Helsinki, Good Clinical Practice guidelines, and local regulations for 
clinical trials. The study protocol was approved by the Independent 
Local Ethics Committee of each participating center. Signed informed 
consent was obtained from all patients prior to any study-specific 
procedure. 
2.2. Study treatment 
Patients received lurbinectedin 3.2 mg/m2 administered as a 1 -h 
intravenous (i.v.) infusion every 3 weeks (q3wk) until disease progres-
sion or unacceptable toxicity. All patients received antiemetic prophy-
laxis. Primary prophylaxis with granulocyte colony-stimulating factors 
(G-CSFs) was not allowed. Up to 2 dose reductions were allowed, from 
3.2 to 2.6 and then to 2.0 mg/m2. 
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2.3. Outcomes 
Subgroup analyses by CTFI were pre-planned in this study. The pri-
mary endpoint was the ORR according to RECIST v1.1, supported by 
duration of response (DoR; defined as the date of first response to the 
date of disease progression, relapse or death due to any cause) as sec-
ondary endpoint, both assessed by the Investigators. Blinded image re-
view was conducted by an Independent Review Committee to confirm 
radiological results. Secondary endpoints included disease control rate 
(defined as objective response plus stable disease as best response); PFS 
(defined as the time from the date of first infusion to the date of disease 
progression, death of any cause, or last tumor evaluation); OS (defined 
as the time from the date of first infusion to the date of death or last 
contact in case of patients lost to follow-up or alive at the clinical cut- 
off), and safety. 
2.4. Assessments 
Radiological assessments were done every 6 weeks until cycle 6, and 
every 9 weeks thereafter. Responses were confirmed at least 4 weeks 
later. Safety was evaluated in all patients who received at least one 
lurbinectedin infusion, complete or incomplete, by assessment of 
adverse events (AEs), clinical laboratory tests, physical examinations 
and vital signs. Safety was monitored throughout the treatment and up 
to 30 days after last lurbinectedin infusion, or until the patient started a 
new antitumor therapy or until the date of death, whichever occurred 
first. All patients were followed until recovery from any lurbinectedin- 
related AE. 
2.5. Statistical analysis 
This exploratory assessment is based on a pre-planned analysis by 
CTFI. Descriptive statistics were used. Non-continuous variables are 
described in frequency tables using counts and percentages. Continuous 
variables are described by median, minimum and maximum. Binomial 
exact estimates and its 95 % confidence interval were calculated for the 
evaluation of the main endpoint (ORR). The Kaplan-Meier method was 
used to analyze DoR, PFS and OS. AEs were recorded and coded with the 
Medical Dictionary for Regulatory Activities (MedDRA), v.21.0. AEs and 
laboratory values were graded per the National Cancer Institute- 
Common Toxicity Criteria for Adverse Events (NCI-CTCAE), v.4.0. SAS 
software (v. 9.4) was used to generate statistical outputs. 
3. Results 
Twenty patients treated with lurbinectedin in this phase II study had 
CTFI ≥ 180 days and form the basis for this analysis. Their baseline 
characteristics are shown in Table 1. Patients were mostly males (60.0 
%), had ECOG PS 0− 1 (95.0 %), and had a median age of 57 years 
(range, 49− 75 years). Extensive stage disease at initial diagnosis was 
present in 7 patients (35.0 %). All 20 patients had received prior plat-
inum/etoposide, with no prior immunotherapy. An objective response 
to first-line therapy was observed in 85 % of the patients. Median CTFI 
was 7.5 months (range, 6.0− 16.1). 
ORR assessed by the Investigators was 60.0 % (12/20 patients) (95 % 
CI, 36.1− 86.9) (Table 2), with a median DoR of 5.5 months (95 %CI, 
2.9− 11.2) and disease control rate of 95.0 % (95 %CI, 75.1− 99.9). ORR 
assessed by independent review was 50.0 % (95 %CI, 27.2− 72.8), with a 
median DoR of 5.5 months (95 %CI, 2.8− 8.5) and disease control rate of 
80 % (95 %CI, 56.3− 94.3). 
The median PFS was 4.6 months (95 %CI, 2.6− 7.3). Eleven patients 
(55.0 %) were censored for survival analysis: eight patients were on 
follow-up after disease progression, two patients were ongoing lurbi-
nectedin treatment, and one patient had treatment discontinuation 
because of a treatment-related adverse event (this patient had a partial 
response but, after 6 cycles, grade 1 peripheral neuropathy present at 
study entry worsened to grade 2). With a median follow-up of 15.6 
months, the median OS was 16.2 months (95 %CI, 9.6-upper level not 
reached). Of note, 60.9 % and 27.1 % of patients were alive at 1 and 2 
years, respectively (Table 2). 
All 20 patients were evaluable for safety (Table 3). The median 
number of lurbinectedin cycles administered per patient was 6 (range, 
2–24) for a total of 159 cycles. The most common grade 3/4 AEs and 
laboratory abnormalities were hematological disorders, including neu-
tropenia (55.0 %), anemia (10.0 %) and thrombocytopenia (10.0 %), as 
well as fatigue (10.0 %) and increased liver function tests (GGT, 10 %; 
ALT and AP, 5.0 % each). Of note, no cases of febrile neutropenia were 
observed in this subset of patients. 
Treatment delay and dose reduction because of treatment-related 
events was required in 8 (5.8 %) and 9 cycles (9.5 %), respectively, 
mainly because of transient neutropenia. 
No treatment-related deaths occurred: 9 patients (45.0 %) died 
during the study period due to disease progression. 
4. Discussion 
The NCCN guidelines [2] state re-challenge with the original 
first-line treatment as a preferred treatment and lurbinectedin as other 
recommended regimen in SCLC patients with relapse and CTFI ≥ 180 
days. Evidence on re-challenge effects was obtained from small clinical 
Table 1 
Baseline characteristics in SCLC patients with CTFI ≥ 180 days (n = 20).   
n % 
Gender   
Male 12 60⋅0 
Female 8 40⋅0 
Age. median (range), years 57 (49− 75) 
ECOG PS status   
0 10 50.0 
1 9 45.0 
2 1 5.0 
Abnormal LDH (>ULN) 5 25.0 
Smoker status   
Former/current 18 90.0 
Never 2 10.0 
Stage at diagnosis   
Limited 13 65.0 
Extended 7 35.0 
No. of sites at baseline, median (range) 3 (1− 5) 
Most common sites other than lung  
Lymph nodes 16 80.0 
Adrenal 5 25.0 
Liver 4 20.0 
Bulky disease (one lesion >50 mm) 4 20.0 
CNS involvement 2 a 10.0 
Paraneoplastic syndrome 1 5.0 
Prophylactic cranial irradiation 15 75.0 
No. of prior lines. median (range) 1 (1− 2) 
1 line 19 95.0 
2 lines 1 b 5.0 
Prior agents  
Platinum compounds 20 100.0 
Etoposide 20 100.0 
Immunotherapy 0 0.0 
Best response to prior platinum   
CR 7 35.0 
PR 10 50.0 
SD 3 15.0 
CTFI, median (range), months 7.5 (6.0− 16.1) 
Data shown are n (%) of patients except for median (range). 
CR, complete response; CTFI, chemotherapy-free interval; ECOG PS, Eastern 
Cooperative Oncology Group Performance Status; LDH, lactate dehydrogenase; 
PR, partial response; SD, stable disease; ULN, upper limit of normal. 
a One patient had CNS metastases at baseline (protocol deviation) an other 
CNS history prior to study entry. 
b One patient was treated with a second line consisting of an investigational 
drug (GSK52572). 
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trials conducted in the 1980s [21,22]. Some of these old trials did not 
use platinum-based therapy as the first-line treatment and, therefore, the 
NCCN recommendation is to re-treat with the initial treatment, and not 
specifically with platinum-based therapy. Re-challenge with the initial 
first-line regimen is also stated in the ESMO guidelines as follows: Only 
patients with sensitive disease derive benefit from re-challenge with first-line 
therapy (usually platinum-etoposide) [V.C] [1]. Nevertheless, “V” level 
evidence comes from studies without control group, case reports and 
experts opinion. The “C” recommendation stated in ESMO guidelines, 
therefore, indicates insufficient evidence for efficacy or that the benefit 
does not outweigh the risk or the disadvantages (adverse events, costs), 
and is considered optional. Although the level of evidence is low, 
re-challenge seems to be widely used in daily clinical practice. 
Table 4 shows the outcomes observed in the most recent studies on 
platinum re-challenge compared to those observed with lurbinectedin in 
patients with CTFI ≥ 90 days and CTFI ≥ 180 days. Acknowledging the 
inherent limitations of cross-trial comparison, the small patient pop-
ulations evaluated, the specific characteristics of Japanese patients in 
terms of benefit/risk profile compared to white patients, and the limi-
tations of the study B-005 (single-arm design with no control group and 
exclusion of patients with brain metastases), the results reported here in 
the subset of patients recommended by the NCCN guidelines (patients 
with CTFI ≥ 180 days) show remarkable ORR (60 %) and median OS 
(16.2 months) when compared with previous studies on platinum re- 
challenge [6,7], where ORR was 43–46 % and median OS was 
14.3–15.7 months (Table 4). The efficacy outcomes previously reported 
with lurbinectedin in the CTFI ≥ 90 days subset [19] showed similar 
ORR but longer OS (11.9 months vs. 7.5–7.9 months) when compared 
with the largest studies [8,12]. This is a relevant finding because, since 
1997, no chemotherapy regimens have demonstrated improvement in 
survival in second-line and beyond SCLC [23]. There is a desperate need 
for new approaches in this setting. An additional benefit of lurbinectedin 
as second-line therapy in patients with sensitive SCLC is prolongation of 
the platinum-free interval, which may further re-sensitize tumors to the 
original therapy for a third-line therapy [24]. After lurbinectedin, 7 of 
20 patients (35 %) received further platinum. 
The decision-making patterns in Europe for second-line treatment in 
real world practice were recently analyzed [25]. The two criteria most 
relevant to decision-making were performance status and the interval to 
recurrence since first-line treatment. In agreement with the clinical 
guidelines, consensus for platinum re-challenge as the preferred treat-
ment for SCLC patients with CTFI ≥ 180 days was agreed by 92 % of the 
European experts consulted (no consensus was observed on the 
second-line therapy with a CTFI between 90 and 180 days). A study 
evaluating real-world treatment patterns of patients with SCLC in the 
EU, US and Japan showed that approximately half of patients with 
sensitive disease were not re-challenged with platinum-based therapy 
across all regions [26]. Although these two real-world analyses [25,26] 
did not include results of efficacy, real-world efficacy data are available 
from the prospective clinical cohort German study TLK [27]. Subset 
analysis of 31 patients undergoing second-line re-treatment with a 
platinum-based regimen after a median CTFI of 6.6 months, including 
55 % with CTFI ≥ 90 days, demonstrated an ORR of 38.7 % and median 
OS of 8.0 months (95 %CI, 6.8–16.5 months). A systematic literature 
review on real-world effectiveness and tolerability of SCLC treatments 
showed a median OS of 6.3 months for patients with sensitive disease 
treated with chemotherapy as second-line [28]. Overall, lurbinectedin 
data compares favorably with respect to these real-world figures. 
Lurbinectedin survival in the subset of CTFI ≥ 180 days also com-
pares favorably to outcomes on topotecan (median survival of 8.2 
months; 1-year survival rate of 32.3 %) per a pooled analysis from six 
studies with intravenous topotecan in 200 SCLC patients with CTFI of 
180 days [29]. 
Lurbinectedin 3.2 mg/m2 1 -h q3wk regimen has an acceptable and 
manageable safety profile, with the main toxicity being reversible 
myelosuppression. Primary G-CSF prophylaxis is not required [19]. In 
this subset of 20 patients treated with lurbinectedin, grade 3/4 neu-
tropenia was reported in 45 % of patients, with no cases of febrile 
neutropenia, and grade 3/4 thrombocytopenia was reported in 10 %. 
Febrile neutropenia occurred in 5% of the overall SCLC population 
receiving lurbinectedin [19]. Limited information is available on 
adverse events with platinum re-challenge in SCLC relapsed patients. 
Although it is known that, apart from myelotoxicity, platinum 
re-challenge affects renal function and is associated to neuropathy and 
ototoxicity, until now there was not alternative option beyond top-
otecan. Recently, Monnet et al. [12] reported grade 3/4 neutropenia in 
23 % of patients with re-challenge vs. 36 % with topotecan; febrile 
neutropenia in 6% vs. 10 % (primary G-CSF allowed), grade 3/4 anemia 
in 30 % vs. 22 %, and grade 3/4 thrombocytopenia in 41 % vs. 38 %. 
Table 2 
Efficacy data in SCLC patients treated with lurbinectedin and chemotherapy-free 
interval ≥180 days (n = 20).   
Investigator Independent 
review 




Best overall response, n, (%)   
PR 12 (60.0) 10 (50.0) 
SD 7 (35.0) 6 (30.0) 
PD 1 (5.0) 4 (20.0) 
Disease control rate (ORR + SD), n 





Median DoR, months (95 %CI) 5.5 (2.9− 11.2) 5.5 (2.8− 8.5) 
Median PFS, months (95 %CI) 4.6 (2.6− 7.3) 4.6 (2.3− 7.6) 
Median OS, months b (95 %CI), 16.2 (9.6-nr) 
OS at 12 months, % (95 %CI) 60.9 (35.7− 86.2) 
CI, confidence interval; CTFI, chemotherapy-free interval; nr, not reached; ORR: 
overall response rate; PD, progressive disease; PFS, progression-free survival; 
PR, partial response; OS, overall survival; SD, stable disease. 
a Confirmed responses. 
b Eleven patients (55.0 %) were censored for survival analysis: eight were on 
follow-up after disease progression, two were ongoing lurbinectedin treatment, 
and one had treatment discontinuation because of a treatment-related adverse 
event (worsening of prior peripheral neuropathy). Median follow-up was 15.6 
months. 
Table 3 
Most common treatment-related adverse events and laboratory abnormalities 
(>10 % of patients or grade≥3) in SCLC patients treated with lurbinectedin and 
chemotherapy-free interval ≥180 days (n = 20).   
NCI-CTCAE grade 
Grade 1− 2 Grade 3 Grade 4 
n (%) n (%) n (%) 
Treatment-related adverse events 
Fatigue 11 (55.0) 2 (10.0) ⋅⋅ 
Diarrhea 4 (20.0) ⋅⋅ ⋅⋅ 
Constipation 3 (15.0) ⋅⋅ ⋅⋅ 
Decreased appetite 3 (15.0) ⋅⋅ ⋅⋅ 
Nausea 3 (15.0) ⋅⋅ ⋅⋅ 
Hematological abnormalities (regardless of relationship) 
Anemia 17 (85.0) 2 (10.0) – 
Neutropenia 5 (25.0) 2 (10.0) 9 (45.0) 
Thrombocytopenia 4 (20.0) – 2 (10.0) 
Biochemical abnormalities (regardless of relationship) 
Creatinine increased a 16 (80.0) ⋅⋅ ⋅⋅ 
ALT increased 14 (70.0) 1 (5.0) ⋅⋅ 
GGT increased 12 (60.0) 1 (5.0) 1 (5.0) 
AST increased 6 (30.0) ⋅⋅ ⋅⋅ 
AP increased 5 (25.0) 1 (5.0) ⋅⋅ 
AP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate 
aminotransferase; GGT, gamma glutamyltransferase; NCI-CTCAE, National 
Cancer Institute Common Terminology Criteria for Adverse Events v⋅4. 
a Version 4⋅0 of NCI-CTCAE grades creatinine increases from baseline, even if 
creatinine values remain normal. 




Main efficacy and safety outcomes in patients with sensitive SCLC (CTFI ≥ 90 and ≥180 days): platinum re-challenge and lurbinectedin.   
CTFI ≥ 90 days CTFI ≥ 180 days  




Korkmaz Inoue Wakuda Genestreti Shiozawa Naito Wakuda Monnet Trigo Wakuda Current 
analysis (2013) [5] (2015) [6] (2015) [7] (2015) [8] (2018) [9] (2018) [10] (2019) [11] (2019) [12] (2020) [19] (2015) [7] 
STUDY DESIGN Retrospective Phase II 
randomized 
Retrospective Retrospective Retrospective Retrospective 
analysis 
Retrospective Phase III Phase II Retrospective Phase II 
(n) analysis 
(n = 33) 
(n = 30) analysis analysis analysis (n = 67) analysis randomized single-arm analysis single-arm    
(n = 19) (n = 112) (n = 20)  (n = 27) (n = 81) (n = 60) (n = 11) (n = 20) 
Median CTFI 
NA 
60 % CTFI 7.1 7.9 3.8 5.9 6.6 5.3 4.8 8.8 7.5 
(range) >180 days (3.1− 39.2) (3.0− 39.5) (3.0− 13.2) (3.1− 50.0) (3.1− 38.7) (4.7− 5.8) (3.0− 16.1) (6.0− 38.7) (6.0− 16.1) 
Age (years), median (range) 
58 67 69 64 65 NA 66 64 59 69 57 
(NA) (45–80) (51− 83) (40− 83) (52–84)  (51− 73) (NA) (44− 79) (52− 79) (49− 75) 
Response first line % NA NA 95 % 98 % NA NA 98 % NA 85 % 100 % 85 % 
Limited disease, % 39 % 60 % 63 % 44 % 55 % 49 % 44 % NA 42 % 73 % 65 % 
ECOG PS 0− 1, % 82 % 93 % 95 % 87 % 90 % 85 % 89 % 94 % 95 % 91 % 95 % 
EFFICACY OUTCOMES   
ORR, % 55 43 37 45 50 52 48 49 45 46 60 
(95 %CI) (NA) (28–58) (19− 59) (NA) (NA) (NA) (NA) (NA) (32− 58) (21− 72) (36− 87) 
Disease control rate, % NA 80 84 64 80 82 74 86 82 73 95 
(95 %CI)  (68− 92) (NA) (NA) (NA) (NA) (NA) (NA) (70− 91) (NA) (75− 100) 
PFS (months), median 6.2 5.1 5.6 5.5 4.5 5.1 5.5 4.7 4⋅6 7.8 4.6 
(95 %CI) (NA) (NA) (NA) (4.4− 6.3) (3.5− 5.4) (4.3− 5.4) (3.4− 6.1) (3.9− 5.5) (2.8–6.5) (NA) (2.6− 7.3) 
OS (months), median 11.4 14.3 14.4 7.9 10.5 10.8 14.2 7.5 11.9 15.7 16.2 
(95 %CI) (NA) (NA) (NA) (6.9− 9.7) (7.9− 13.0) (8.7–14.5) (6.4− 25.6) (5.4− 9.5) (9.7− 16.2) (NA) (9.6-nr) 
SAFETY OUTCOMES   
Primary G-CSF use NA No NA NA NA NA NA Yes No NA No 
Grade 3/4 neutropenia, % NA 73 % 94 % NA 65 % NA 85 % 23 % 46 % NA 45 % 
Febrile neutropenia, % NA 0% 16 % NA 15 % NA 19 % 6% 5% NA 0% 
Grade 3/4 
thrombocytopenia, % 
NA 27 % 26 % NA 10 % NA 37 % 41 % 7% NA 10 % 
Grade 3/4 fatigue, % NA 3% 0% NA 0% NA 11 % 7% 7% NA 10 % 
CI, confidence interval; CTFI, chemotherapy-free interval; ECOG PS, Eastern Cooperative Oncology Group performance status; PFS, progression-free survival; NA, not available; nr, not reached (upper level); ORR, overall 
response rate; OS, overall survival. 
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Studies in Japanese patients treated with platinum re-challenge have 
shown grade 3/4 neutropenia in 65–94 % of patients, febrile neu-
tropenia in 15–19 %, and grade 3/4 thrombocytopenia in 27–37 % 
(Table 4). Grade 3/4 fatigue, the other common adverse event with 
lurbinectedin, is similar than that reported with re-challenge (10 % vs. 
3–11 %). 
In conclusion, lurbinectedin is an effective treatment for platinum- 
sensitive relapsed SCLC, with remarkable activity in patients with 
CTFI ≥ 180 days. In addition, this drug has acceptable safety and 
tolerability, which is particularly favorable in terms of hematological 
toxicity compared to platinum re-challenge. These results suggest that 
lurbinectedin could be a valuable therapeutic alternative to re-treatment 
with the first-line therapy. Further research on larger populations is 
required to confirm this finding. 
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